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Abstract
Objectives: We reviewed testosterone changes for patients who were treated with radiation therapy
(RT) alone on NRG oncology RTOG 9408.
Methods and materials: Patients (T1b-T2b, prostate-specific antigen <20 ng/mL) were random-
ized between RT alone and RT plus 4 months of androgen ablation. Serum testosterone (ST) levels
were investigated at enrollment, RT completion, and the first follow-up 3 months after RT. The
Wilcoxon signed rank test was used to compare pre- and post-treatment ST levels in patients who
were randomized to the RT-alone arm.
Results: Of 2028 patients enrolled, 992 patients were randomized to receive RT alone and 917
(92.4%) had baseline ST values available and completed RT. Of these 917 patients, immediate and
3-month post-RT testosterone levels were available for 447 and 373 patients, respectively. Exclud-
ing 2 patients who received hormonal therapy off protocol after RT, 447 and 371 patients, respectively,
were analyzed. For all patients, the median change in ST values at completion of RT and at 3-month
follow-up were −30.0 ng/dL (p5-p95; −270.0 to 162.0; P < .001) and −34.0 ng/dL (p5-p95, −228.0
to 160.0; P < .01), respectively.
Conclusion: RT for prostate cancer was associated with a median 9.2% decline in ST at comple-
tion of RT and a median 9.3% decline 3 months after RT. These changes were statistically significant.
© 2017 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Various studies in the contemporary radiation therapy
(RT) literature have evaluated changes in serum testoster-
one (ST) levels for patients receiving external beam RT for
prostate cancer1-9 and other pelvic malignancies.10-13 The ma-
jority of these studies have indicated that these patients
experience a decline in ST after RT. Low-dose scatter ra-
diation to the testicular Leydig cells is believed to be the
most likely explanation for this phenomenon. The current
study evaluates the changes in ST observed in patients who
were enrolled and treated in the NRG oncology RTOG 9408
study.
Methods and materials
From 1994 through 2001, 1979 eligible patients with
stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and
a prostate-specific antigen (PSA) level of 20 ng/mL or less
were randomly assigned to RT alone or RT with 4 months
of total androgen suppression starting 2 months before RT.
The primary endpoint for the study was overall survival.
The secondary endpoints included disease-specific mor-
tality, distant metastases, biochemical failure (eg, an
increasing PSA level), and the rate of positive findings on
the planned repeat prostate biopsy at 2 years. The details
of the study design and outcomes are well described in a
prior publication.14 RT consisted of either whole pelvic RT
(WPRT) to 46.8 Gy plus a 19.8 Gy prostate boost for a total
dose of 66.6 Gy or RT to the prostate only (PORT) for a
total dose of 68.4 Gy. Typical field arrangements are shown
in Figure 1a and 1b.
Most patients received WPRT. Only patients with the
lowest-risk features (PSA <10 ng/mL and Gleason score ≤5
or a negative lymph node dissection) were assigned to
receive PORT. RT was delivered at 1.8 Gy per fraction. For
this analysis, ST levels were investigated at the following
collection periods: study enrollment; completion of RT; and
first follow-up 3 months after completion of RT. The
Wilcoxon signed-rank test was used to compare the change
in pre- and post-treatment ST levels (at completion of RT
and at the 3-month follow-up visit) in patients who were
randomized to the RT-alone arm. The same paired differ-
ences were further compared between WPRT and PORT,
and a Wilcoxon signed-rank test was used to detect any sta-
tistically significant differences. Two different follow-up
periods were analyzed: end of RT and first post-RT follow-
up. All statistical tests were carried out at the 0.05
significance level. Although it is well recognized that ST
levels are subject to diurnal variation, given the large number
of patients evaluated, it is unlikely that the results were
skewed by any systematic bias as a result of the time of
day blood samples were drawn. All laboratory testing was
performed at laboratories that were chosen by the institu-
tion that enrolled the patient in the study. As such, there
was no standardization of the results. Institutional review
board approval of the protocol and consent documenta-
tion were obtained at each participating institution. All
patients signed informed consent prior to study enrollment.
Results
Of the 1979 eligible patients enrolled in the NRG on-
cology RTOG 9408 study, 992 were randomized to receive
RT alone and 925 (93%) had baseline ST values avail-
able. Of these 925 patients, 917 (99%) completed RT. Of
these 917, 447 had ST information available at the end of
RT. None of the 447 patients received hormonal therapy
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off protocol before the study evaluation. A total of 373 pa-
tients had ST values available 3 months after completion
of RT. Two of the 373 patients had received hormonal
therapy off protocol prior to this evaluation, leaving 371
patients for analysis at that time point. The outliers were
included in all analyses. A breakdown of the patients evalu-
ated is shown in Table 1. The pretreatment characteristics
of the analyzable patients are shown in Table 2.
For the entire group of patients who completed RT and
had no prior hormonal therapy, the median change in ST
was −30.0 ng/dL at the end of RT (P < .001) and −34.0 ng/dL
3 months post-RT (P < .001). The distribution is shown in
Table 3.
For the subgroup of patients who were treated with
WPRT and completed RT and who had no prior hor-
monal therapy, the median change in ST was −35.3 ng/dL
(n = 386) at the end of RT (P < .001) and −31.4 ng/dL
(n = 320) 3 months post-RT (P < .001). The distribution is
shown in Table 3, and the relative changes are shown in
Table 4.
For the subgroup of patients who were treated with PORT
and completed RT and who had no prior hormonal therapy,
the median change in ST was −11.0 ng/dL (n = 61) at the
end of RT (P = .13) and −41.0 ng/dL (n = 51) 3 months post-
RT (P < .001). The distribution is shown in Table 3 and the
relative changes are shown in Table 4. The difference in
the median change in ST between the WRPT and PORT
groups was not statistically significant at either the end of
RT (P = .216) or 3 months after RT (P = .277).
An effort was made to correlate change in ST with
change in sexual function. A total of 337 patients in the RT-
alone group completed an initial Sexual Adjustment
Questionnaire (SAQ), and 270 patients completed the SAQ
12 months after treatment. However, from the group of pa-
tients who completed both SAQs, we identified only 73
patients who also had baseline and 3-month ST data avail-
able. This small number of evaluable patients presented
problems on 2 levels. First, there was the unlikelihood that
our analysis would have the statistical power to correlate
Figure 1 Regional lymphatics target volumes. Shown are typical whole pelvis (a) and prostate boost (b) fields used to treat patients
enrolled on NRG oncology RTOG 9408. The testicles (in yellow) are shown to be well outside of the radiation therapy beam paths.
Table 1 Availability of serum testosterone levels for patients
in the radiation therapy alone arm of NRG oncology RTOG 9408
(n = 992)
Group No. of patients
Total sample 992
With baseline testosterone 925
With baseline testosterone and completed RT 917
With baseline and end of RT testosterone 447
With baseline and 3-month post-RT testosterone 371a
RT, radiation therapy.
a Two patients were excluded because of hormone initiation.
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ST change with a change in sexual function. Second, because
these 73 patients only represented 22% of the 337 pa-
tients who answered the initial SAQ, from a missing data
analysis perspective, conclusions could be unreliable and
misleading. As such, we are unable to offer a meaningful
correlation between changes in ST and change in sexual
function.
Discussion
The current study represents the second largest series
in the RT literature to evaluate changes in ST in patients
receiving RT for localized prostate cancer and the largest
study based on data collected as part of a large-scale pro-
spective multi-institutional trial. Although a large share of
the posttreatment testosterone data were not collected (only
447 patients had ST levels drawn at the end of RT and 371
at 3 months after RT), we believe that this was a function
of the decentralized nature of data collection. We do not
believe that this introduces systemic bias into the analy-
sis. Although only short-term data were collected, the
findings are consistent with most previously published
studies that demonstrate a decline in ST after photon-
based RT. These studies stand in contrast to recently
published studies that fail to demonstrate such testoster-
one changes after proton-based RT or brachytherapy. Table 5
lists the 7 studies that were published after 1990, along-
side the current study.
Zagars and Pollack4 reported a 9% decline in ST 3
months after RT in 85 patients treated with RT for pros-
tate cancer. Patients in the series received doses ranging
from 66 to 78 Gy (median, 68 Gy) at 2 Gy per fraction to
the prostate, only specified at the isocenter. No patient was
treated with pelvic nodal RT. The decline in ST was sta-
tistically significant at the P = .0001 level.
Table 2 Pretreatment characteristics of eligible patients
WPRT
(n = 807)
PORT
(n = 110)
Total
(n = 917)
Age (y)
Median 71 70 71
Range 47-84 51-88 47-88
Q1-Q3 66-75 67-73 66-74
Karnofsky performance status
70-80 56 (6.9%) 9 (8.2%) 65 (7.1%)
90-100 751 (93.1%) 101 (91.8%) 852 (92.9%)
Tumor stage
T1 383 (47.5%) 52 (47.3%) 435 (47.4%)
T2 424 (52.5%) 58 (52.7%) 482 (52.6%)
Node stage
N0 16 (2.0%) 16 (14.5%) 32 (3.5%)
NX 791 (98.0%) 94 (85.5%) 885 (96.5%)
Differentiation
Well 96 (11.9%) 44 (40.0%) 140 (15.3%)
Moderately 516 (63.9%) 61 (55.5%) 577 (62.9%)
Poor/undifferentiated 195 (24.2%) 5 (4.5%) 200 (21.8%)
Prostate-specific antigen levels
<4 75 (9.3%) 14 (12.7%) 89 (9.7%)
4-20 732 (90.7%) 96 (87.3%) 828 (90.3%)
Intercurrent disease
Absent 220 (27.3%) 32 (29.1%) 252 (27.5%)
Present 585 (72.5%) 77 (70.0%) 662 (72.2%)
Unknown 2 (0.2%) 1 (0.9%) 3 (0.3%)
Gleason score
2-6 448 (55.5%) 103 (93.6%) 551 (60.1%)
7 257 (31.8%) 4 (3.6%) 261 (28.5%)
8-10 77 (9.5%) 2 (1.8%) 79 (8.6%)
Unknown 25 (3.1%) 1 (0.9%) 26 (2.8%)
Testosterone level (ng/dL)
Median 370.00 352.29 367.00
Range 42.00-1380.40 76.00-800.00 42.00-1380.40
Q1-Q3 280.00-475.00 274.00-454.00 279.00-466.00
PORT, prostate-only radiation therapy; Q1, first quartile; Q3, third quartile; WPRT, whole pelvis radiation therapy.
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Table 3 Absolute changes in serum testosterone levels
Baseline to end of RT Baseline to 3 months post-RT
All
(n = 447)
WPRT
(n = 386)
PORT
(n = 61)
All
(n = 371)
WPRT
(n = 320)
PORT
(n = 51)
Minimum −608.07 −608.07 −293.95 −478.39 −478.39 −315.85
5th percentile −270.00 −288.18 −178.67 −228.00 −240.50 −182.00
Q1 −109.00 −110.00 −57.64 −99.00 −100.50 −86.46
Median −30.00 −35.29 −11.00 −34.00 −31.35 −41.00
Q3 38.62 40.00 29.00 32.00 41.61 15.00
95th percentile 162.00 172.00 125.00 160.00 169.00 65.00
Maximum 593.66 593.66 158.50 691.00 691.00 86.46
P-valuea < .001 < .001 .128 < .001 < .001 < .001
P-valueb .216 .277
PORT, prostate-only radiation therapy; Q1, first quartile; Q3, third quartile; RT, radiation therapy; WPRT, whole pelvis radiation therapy.
a P-value from Wilcoxon signed-rank test comparing to 0.
b P -value comparing WPRT vs. PORT from Wilcoxon test.
Table 4 Relative changes in serum testosterone levels
Baseline to end of RT Baseline to 3 months post-RT
All
(n = 447)
WPRT
(n = 386)
PORT
(n = 61)
All
(n = 371)
WPRT
(n = 320)
PORT
(n = 51)
Minimum −96.5% −96.5% −53.4% −96.8% −96.8% −69.7%
5th percentile −51.1% −52.6% −43.5% −46.4% −46.6% −45.1%
Q1 −27.3% −27.8% −14.4% −25.8% −26.1% −24.0%
Median −9.2% −10.0% −2.5% −9.3% −9.1% −13.5%
Q3 12.8% 13.0% 12.4% 9.5% 13.6% 4.8%
95th percentile 59.1% 59.1% 53.0% 53.1% 57.9% 22.2%
Maximum 173.1% 173.1% 78.6% 179.2% 179.2% 28.6%
P-valuea < .001 < .001 .354 < .001 .001 .001
P valueb .172 .348
Q1, first quartile; Q3, third quartile; PORT, prostate-only radiation therapy; RT, radiation therapy; WPRT, whole-pelvis radiation therapy.
a P-value from Wilcoxon Signed-Rank test comparing to 0.
b P-value comparing WPRT vs. PORT from Wilcoxon test.
Table 5 Literature review
Literature No. of patients Modality Dose Serum testosterone change
Zagars et al, 19974 85 2D EBRT 68 Gy (median) 9% decline in mean at 3 months
Daniell et al, 20013 33 2D EBRT 70 Gy (approximate) 27.3% decline at 3 to 8 years versus
prostatectomy patients
Pickles et al, 20022 666 3D CRT 65 Gy (range, 52.5-70 Gy) 17% decline in median at 6 months
Oermann et al, 20111 26 Robotic Radiosurgery SBRT 36.25 Gy 23.7% decline in median at
12 months (P < .013)
Nichols et al, 20129 150 Protons 78-82 Gy (RBE) No significant change
Taira et al, 201215 221 Pd-103 BTx ± EBRT Not specified No significant change
Kil et al, 20138 217 Protons 70-72.50 Gy (RBE) No significant change
Current Series 447 2D-EBRT and 3D-CRT 66.6-68.4 Gy 9% decline at 3 months
2D, 2-dimensional; 3D, 3-dimensional; BTx, brachytherapy; CRT, conformal radiation therapy; EBRT, external beam radiation therapy; RBE, rela-
tive biological equivalence; SBRT, stereotactic body radiation therapy.
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Daniell et al3 compared the ST levels of 33 men who
had undergone RT with those of 55 men who had under-
gone radical prostatectomy 3 to 8 years after treatment. The
irradiated patients had a 27.3% lower ST level compared
with the surgically treated patients. The investigators sug-
gested that these findings could be explained by radiation
injury to the testicles.
Pickles et al2 reported on 666 men who were treated with
RT for localized prostate cancer between 1994 and 2001.
No patient received hormonal therapy. According to the in-
vestigators, “few” of the patients received pelvic nodal RT.
The vast majority was treated with fields that were limited
to the prostate. Six months after completion of RT, the mean
ST levels had declined to 83% of the baseline pre-RT levels.
The authors attribute this decline to scatter radiation dose
to the testicles. With further follow-up, the authors noted
a normalization of ST in the vast majority of patients.
Oermann et al1 reported on 26 men with low- or
intermediate-risk prostate cancer treated with stereotactic
body RT (SBRT) with robotic radiosurgery. Patients re-
ceived 36.25 Gy in 5 fractions of 7.25 Gy to the prostate
or prostate and proximal seminal vesicles over a 2-week
period. The authors observed a 23.7% median decline in
ST levels at 1 year, which was significant at the P = .013
level.
One study of testosterone changes after brachytherapy
failed to show declines in ST.15 This lack of testosterone
suppression was seen in patients treated with brachytherapy
alone as well as in patients treated with low-dose external
beam RT (20-45 Gy) plus a brachytherapy boost. The authors
suggest that the lack of testosterone suppression in this
setting is explained by the lower testicular scatter dose as-
sociated with brachytherapy.
Grigsby and Perez5 reported on 59 patients with pros-
tate cancer who received 65 to 70 Gy to the prostate. In
contrast to subsequently published studies, the authors did
not identify significant changes is ST for 24 months after
RT. However, significant declines in dihydroxytestosterone
as well as increases in follicle-stimulating hormone and lu-
teinizing hormone were seen.
In contrast to the majority of studies on testosterone ki-
netics after external photon radiation, 2 recent studies on
proton therapy did not demonstrate posttreatment testos-
terone suppression. Kil et al8 reported on 217 hormone
therapy–naive patients with low- or intermediate-risk pros-
tate cancer who received 70.00 (relative biological
equivalence [RBE]) to 72.50 Gy (RBE) with hypofractionated
passively scattered protons delivered at 2.5 Gy (RBE) per
fraction in a prospective study. The median pretreatment
ST level was 367.7 ng/dL. There were no significant changes
in ST at treatment completion or 6 or 12 months after proton
therapy. The authors imply that the lack of testosterone
suppression after proton therapy, in contrast to the afore-
mentioned studies of photon-based therapies, is consistent
with studies that suggest that passively scattered proton
therapy is associated with less out-of-field low-dose scatter
radiation than photon-based therapy.16-18 Nichols et al9 re-
ported on 150 similar patients from the same institution who
were treated in an earlier prospective study and received
78.00 (RBE) to 82.00 Gy (RBE) with passively scattered
protons delivered at 2.0 Gy (RBE) per fraction. The median
pretreatment ST level was 357.9 ng/dL. There were no sig-
nificant changes in ST at treatment completion or 6, 12,
18, or 24 months after proton therapy.
A number of studies have attempted to estimate or
measure the scatter radiation dose to the testicles in the
setting of prostate RT. Oermann et al1 estimated a median
dose of 2.1 Gy (range, 1.1-5.8 Gy) in the setting of robotic
radiosurgery SBRT. The study by King et al19 estimated that
testicular scatter doses from intensity modulated RT ranged
from 0.84 Gy with PORT to 6.3 Gy in the setting of pelvic
intensity modulated RT with a prostate boost. Previous
studies used thermoluminescence dosimetry (TLD) mea-
surements to estimate the testicular scatter dose to be in
the range of 2 Gy, or approximately 3% of the prescribed
dose to the prostate,2,4,20,21 although an earlier TLD study
by Grigsby5 estimated a testicular dose of 4.5 to 6.0 Gy.
Leydig cell damage may be age dependent, with older
patients experiencing a greater sensitivity to low-dose ra-
diation in the 2 Gy range. Although the aforementioned
studies address the effect of low-dose radiation, or lack
thereof, in older men who are treated for prostate cancer,
2 earlier studies of higher-dose testicular irradiation in
younger men showed no effect on ST. The study by Rowley
et al22 involved the irradiation of the testes of 67 male pris-
oners with an age range of 25 to 52 years. The doses ranged
from 0.08 to 6 Gy. The investigators reported that no sig-
nificant effect was found on the ST levels of the irradiated
patients. The study by Shapiro et al23 followed-up 27 men
who had undergone RT for soft-tissue sarcomas. They failed
to show changes in the ST levels within 30 months of follow-
up. The patients in that series had received a wide range
of testicular doses, from 0.01 to 25 Gy.
Conclusions
External beam RT as delivered in the NRG Oncology
RTOG 9408 study was associated with a median 9.3%
decline in ST at 3 months after RT. There was no signifi-
cant difference in this decline between patients who received
WPRT and those who received PORT. These findings are
consistent with most other series in the photon RT litera-
ture and suggest that low-dose scatter radiation outside of
the beam path has a deleterious impact on testicular Leydig
cell function.
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